A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma

Noa Biran, Scott D. Rowley, David H. Vesole, Shijia Zhang, Michele L. Donato, Alan P. Skarbnik, Joshua Richter, Andrew Pecora, David S. Siegel

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences